Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Is This Biotech Stock Worth the Trouble?
11:00am, Saturday, 23'rd Apr 2022
The past year has been a bit stressful for this company and its shareholders.
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
12:33pm, Friday, 22'nd Apr 2022
Biogen Inc (NASDAQ: BIIB) has decided to withdraw the European marketing authorization application for its troubled Alzheimer's drug, aducanumab, after failing to convince the regulator of its bene
Biogen stock slides 2% after it withdraws authorization application with EU regulator
10:44am, Friday, 22'nd Apr 2022
Biogen Inc. shares BIIB, -2.71% fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial Alzheimer's treatment aducanumab with the European
Biogen Inc. (BIIB) Stock Moves -0.92%: What You Should Know
10:00pm, Thursday, 21'st Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day.
Analyst Ratings for Biogen
06:15pm, Thursday, 21'st Apr 2022 Benzinga
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Is Biogen Stock a Buy Now?
02:53pm, Thursday, 21'st Apr 2022 The Motley Fool
The stock has been surprisingly stable of late, which could be a promising sign.
Down 16% Since October, Could This Stock Make a Turnaround?
02:37pm, Thursday, 21'st Apr 2022 The Motley Fool
Biogen's recent collapse isn't the end of the road by a long shot.
Down 16% Since October, Could This Stock Make a Turnaround?
10:37am, Thursday, 21'st Apr 2022
Biogen's recent collapse isn't the end of the road by a long shot.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
04:10pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
01:33pm, Tuesday, 19'th Apr 2022
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen needs ‘this’ to unlock a 60% upside in its stock
07:51pm, Monday, 18'th Apr 2022 Invezz
Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer’s drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal’s b
Biogen needs ‘this' to unlock a 60% upside in its stock
03:51pm, Monday, 18'th Apr 2022
Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer's drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal's bull
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
03:19pm, Monday, 18'th Apr 2022 Benzinga
Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, whi
Biogen's new Alzheimer's drug could boost the stock by 60%, says Wells Fargo's Mohit Bansal
02:21pm, Monday, 18'th Apr 2022
Mohit Bansal, Wells Fargo Securities senior equity analyst, joins 'The Exchange to discuss drug company Biogen and what its new Alzheimer's drug could mean to the stock.
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
02:04pm, Monday, 18'th Apr 2022 Benzinga
Upgrades
For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q
